AC Immune SA (NASDAQ: ACIU) has released a positive update on its active immunotherapy programs, revealing that three Phase 2 trials are advancing towards significant clinical milestones in 2024. Dr. Andrea Pfeifer, CEO of AC Immune SA, highlighted the consistent clinical development throughout 2023, expressing confidence in the company's robust position as it approaches key milestones for ACI-24.060 in 2024. The focus is on leveraging active immunotherapies from the precision medicine pipeline to slow the onset and prevent neurodegenerative diseases.

The company's financial position received a boost in December through a successful USD50 million equity offering and a CHF15 million milestone payment. This payment is the first of two from a partner related to the Phase 2b ReTain trial of ACI-35.030 in preclinical AD patients. With the second milestone payment expected in 2025, AC Immune has secured sufficient financing to support operations into 2026.

Key updates on specific programs include:

ACI-24.060: AC Immune's anti-amyloid beta (Abeta) active immunotherapy for Alzheimer's disease (AD). The ABATE Phase 1b/2 trial is progressing well, with encouraging immunogenicity results and no safety concerns raised so far. Abeta PET imaging results are expected in H1 2024, and 12-month Abeta PET data are anticipated in H2 2024.

ACI-7104.056: The anti-alpha-synuclein (a-syn) active immunotherapy for Parkinson's disease (PD). Enrollment of cohort 1 in the Phase 2 VacSYn clinical trial is complete, with no reported safety concerns. Updates on safety and immunogenicity from the trial are expected in H2 2024.

ACI-35.030: The investigational targeted active immunotherapy for pathological phosphorylated Tau (pTau). The Phase 2b ReTain trial has been launched to evaluate ACI-35.030 in preclinical AD patients, with a milestone payment received and another expected in 2025 based on achieving enrollment targets.

AC Immune aims to utilize active immunotherapies earlier in the disease progression to prevent permanent damage to neurons, with a focus on precision medicine for neurodegenerative diseases.

 

Source: globenewswire.com

Report Abuse